Table 1 Demographic and clinical characteristics of 75 patients with early rheumatoid arthritis
Characteristics | Early RA N = 75 |
|---|---|
Female, n (%) | 53 (71) |
Age, years, median (IQR) | 49 (38–59) |
Disease duration, months, median (IQR) | 7 (3–12) |
Core disease activity indexes | |
 28TJC, median (IQR) | 8 (5–13) |
 28SJC, median (IQR) | 6 (3–9) |
 PtGA, median (IQR) | 5.5 (4–8) |
 PrGA, median (IQR) | 5 (4–7) |
 ESR, mm/h, median (IQR) | 67 (38–81) |
 CRP, mg/L, median (IQR) | 39 (13–63) |
 RF positive rate, n (%) | 53 (71) |
 ACPA positive rate, n (%) | 56 (75) |
 DAS28-CRP, median (IQR) | 5.1 (4.2–6.1) |
 SDAI, median (IQR) | 28 (20–41) |
 CDAI, median (IQR) | 25 (17–34) |
 HAQ-DI score, median (IQR) | 1.0 (0.3–1.8) |
 Functional limitation△, n (%) | 38 (51) |
Radiographic assessment | |
 mTSS, median (IQR) | 8 (3–25) |
 JSN subscore, median (IQR) | 1 (0–4) |
 Erosion subscore, median (IQR) | 6 (2–22) |
 Bone erosions, n (%) | 64 (85) |
Prior therapy during 3 months before recruitment | |
 Treatment-naïve△△, n (%) | 44 (59%) |
 Glucocorticoids, n (%) | 19 (25) |
 Methotrexate, n (%) | 18 (24) |
 Leflunomide, n (%) | 8 (11) |
 Salazosulfadimidine, n (%) | 4 (5) |
 hydroxychloroquine, n (%) | 6 (8) |
 Biological DMARDs, n (%) | 3 (4) |
 Chinese patent medicine, n (%) | 12 (16) |